Anti–CTLA-4 therapy requires an Fc domain for efficacy

Ipilimumab, a monoclonal antibody that recognizes cytotoxic T lymphocyte antigen (CTLA)-4, was the first approved “checkpoint”-blocking anticancer therapy. In mouse tumor models, the response to antibodies against CTLA-4 depends entirely on expression of the Fcγ receptor (FcγR), which may facilitate...

全面介紹

Na minha lista:
書目詳細資料
發表在:Proc Natl Acad Sci U S A
Main Authors: Ingram, Jessica R., Blomberg, Olga S., Rashidian, Mohammad, Ali, Lestat, Garforth, Scott, Fedorov, Elena, Fedorov, Alexander A., Bonanno, Jeffrey B., Le Gall, Camille, Crowley, Stephanie, Espinosa, Camilo, Biary, Tamara, Keliher, Edmund J., Weissleder, Ralph, Almo, Steven C., Dougan, Stephanie K., Ploegh, Hidde L., Dougan, Michael
格式: Artigo
語言:Inglês
出版: National Academy of Sciences 2018
主題:
Biological Sciences
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5899492/
https://ncbi.nlm.nih.gov/pubmed/29581255
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1801524115
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍